© 2012

Influenza Virus Sialidase - A Drug Discovery Target

  • Mark von Itzstein

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Hans Dieter Klenk
    Pages 1-29
  3. John M. Nicholls, Jimmy Lai, Jean-Michel Garcia
    Pages 31-45
  4. Jefferson Chan, Andrew J. Bennet
    Pages 47-66
  5. Jeffrey C. Dyason, Mark von Itzstein
    Pages 67-75
  6. Hansjörg Streicher, Mathew Stanley
    Pages 105-129
  7. Marie-Anne Rameix-Welti, Sandie Munier, Nadia Naffakh
    Pages 153-174
  8. Back Matter
    Pages 175-178

About this book


Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge.

This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic.


Avian influenza Drug design Infectious diseases Neuraminidase Sialic acid Sialidase inhibitors Tamiflu Viral-receptor interaction

Editors and affiliations

  • Mark von Itzstein
    • 1
  1. 1.Gold Coast Campus, Inst. GlycomicsGriffith UniversitySouthportAustralia

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods